Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822586 · ClinicalTrials.gov registry record · Phase 1
TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02822586 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 5 participants.
The verdict
NCT02822586, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the cutaneous toxicity and treatment response associated with administering concurrent TSEB and brentuximab vedotin in patients with mycosis fungoides or Sézary Syndrome.
Interventions
- DRUG Brentuximab vedotin
- RADIATION TSEB Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2019-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02822586
The ClinicalTrials.gov registry entry for NCT02822586 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brentuximab vedotin is the first listed.
NCT02822586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02822586 about?
NCT02822586 is a clinical study titled "TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome". The purpose of this study is to evaluate the cutaneous toxicity and treatment response associated with administering concurrent TSEB and brentuximab vedotin in patients with mycosis fungoides or Sézary Syndrome.
What is the current status of trial NCT02822586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2016-12-19. Estimated completion is 2019-04-29.
What interventions are being tested in trial NCT02822586?
The interventions under investigation include: Brentuximab vedotin (DRUG), TSEB Therapy (RADIATION).
Who is sponsoring clinical trial NCT02822586?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.